Unity Arc works alongside familiar qualitative and quantitative research workflows, then helps teams make clearer decisions from the evidence.
Pharma teams already use primary research to test positioning, narratives, messages, concepts, campaigns, assets, launch plans, and local adaptations.
The harder question comes after the readout: what should the team back, refine, protect, or take forward?
Unity Arc is built for that moment. It keeps the research entry point familiar, then adds a clearer decision read on what the evidence means for brand, strategy, creative, launch, and market execution.
For insight and brand leaders who need primary research to stay rigorous and familiar, while creating clearer decisions for brand, commercial, medical, and senior teams.
It sits alongside the existing workflow and strengthens the decision read after evidence is collected.
Teams can use Unity Arc within familiar qualitative or quantitative studies: positioning, narrative, message, concept, campaign, IVA, asset, launch, or local adaptation research. The research process stays recognisable. Unity Arc adds a structured read on what the evidence means for the decision.
The difference is reproducibility. Unity Arc reads the same evidence the same way every time.
Most AI tools available to pharma today are generative — they produce a written summary that varies run to run, prompt to prompt, model version to model version. Unity Arc does not generate. It reads the evidence through a fixed decision vocabulary, applied the same way every time. Same input. Same read. Across runs, across markets, across the brand lifecycle. For leadership, that is the difference between a research output that can drift and an evidence layer that can be defended — to legal, to medical, to global, to the agency, and to the board. It is the kind of evidence base brand decisions of this stakes are starting to require.
Not for a scoped project.
It can be added as an analytics and interpretation layer within existing research, procurement, privacy, compliance, and reporting processes. The aim is not to create a new operating burden. The aim is to make the existing research investment work harder.
It turns findings into clearer decision evidence.
A standard output shows what people said, selected, rated, preferred, questioned, or resisted. Unity Arc helps clarify what is driving confidence, what is only surface agreement, what remains fragile, what language can travel, and what should happen next. This is not generative summarisation. It is a structured read that anchors the decision in the same evidence vocabulary every time.
Where research needs to guide a real brand decision.
It is most useful when the team needs to decide what to back, refine, protect, scale, or brief into execution. If the research only needs to answer a narrow question, standard reporting may be enough. If the decision matters, Unity Arc adds value.
It helps MR move from reporting findings to enabling decisions.
Unity Arc gives MR a clearer way to show what the research means for brand, commercial, medical, agency, and leadership action. That makes the readout more useful, the recommendation easier to defend, and the evidence more likely to influence what happens next.
No. And that is a leadership question, not just a procurement one.
Most AI tools available to pharma today are designed to absorb the data that flows through them. Unity Arc is not. Confidential client material — research, transcripts, brand decks, strategy work, creative stimulus, market outputs — supports the client’s decision. It is not used to train external or public models. This is a leadership-level distinction because it determines whether the brand’s IP, evidence base, and strategic thinking stay with the brand. The operating principle is simple, and it should be made explicit in scope before any confidential materials are shared.
For teams who need a controlled way to buy, govern, and evaluate Unity Arc through familiar primary research routes.
Through familiar research and evidence workstreams.
Unity Arc can be added to positioning, narrative, message, concept, campaign, IVA, asset, launch, or local adaptation research. The engagement still has a clear brief, defined stimulus, agreed evidence base, standard outputs, and practical recommendations.
You are buying a scoped, reproducible engagement — not generated output.
A generative AI tool produces text that varies between runs, depending on prompt, context, and model version. The output is not reproducible cleanly, the audit trail is fuzzy, and the procurement model is open-ended. Unity Arc is not generative. It is a structured analytics layer that reads evidence against a fixed decision vocabulary, applied the same way every time. The output is reproducible: same input, same read. That makes the engagement scopable, governable, auditable, and easy to compare across projects. The buying model is closer to a familiar research engagement than to an AI licence — and the procurement controls that already work for research workstreams apply directly.
A primary research engagement with an added decision-read layer.
The core project remains familiar. Unity Arc adds structured interpretation that shows what the evidence supports, where confidence is forming, where caution is needed, and what the organisation can do next. This is not an AI summary tool or an open-ended LLM licence. It is a scoped decision intelligence engagement designed to give pharma teams the same structured read on the same evidence every time.
By reducing duplicated interpretation, rework, and unnecessary follow-on research.
Spend often increases when findings need to be reinterpreted by brand teams, agencies, markets, or leadership after the readout. Unity Arc helps create clearer decision outputs earlier, so teams are less likely to commission extra work just to resolve ambiguity that could have been addressed in the first project.
Start with one live research decision.
Choose a project where the decision matters and compare the Unity Arc output with the standard research output. The test is simple: did it create more decision value from the same research moment? If yes, use it again. If no, stop.
Use the client’s existing NDA, procurement, privacy, and data-handling requirements.
Client research data, transcripts, brand decks, stimulus, and strategy materials should only be used within the agreed scope. The principle is simple: client material supports the client’s decision. It is not used to train a public or external model.
For brand teams who need research to make the next commercial decision easier, not just make the readout more interesting.
Because Unity Arc helps turn research findings into clearer brand action.
Brand teams need to know what to back, what to refine, what to protect, what needs more evidence, and what can move into execution with confidence. Unity Arc makes that decision layer clearer. It does not summarise the research — it structures it for action. The output is not a faster readout. It is a more useful one.
A summary tells you what was said. Unity Arc tells you what it means — the same way every time.
A faster summary is still a summary. It tells the team what respondents said. That is useful, but it is also the thing the team already knows how to do. The harder work is what the evidence means for the brand decision: what is fragile, what should hold, what can flex, what the AOR should protect, what leadership can commit to. Unity Arc reads that layer beneath the surface — and reads it the same way every time. So when the read travels into the agency brief, the launch plan, the local adaptation, the meaning travels with the evidence. The advantage is not speed. The advantage is durability of the strategic call.
It gives agencies clearer guardrails from the evidence.
Research findings often reach agencies as themes, preferences, or recommendations. Unity Arc helps define what must be preserved, what can be adapted, where the evidence is strongest, where the idea is fragile, and what language carries conviction.
It separates strategic consistency from local adaptation.
Unity Arc helps identify what must stay fixed because it carries the brand’s decision logic, and what can flex because it is market-specific, channel-specific, or executional. That gives global teams coherence and local teams clearer freedom.
It makes the next step clearer.
The output helps teams move from “this is what the research found” to “this is what we should do next.” That can shape agency briefs, launch planning, local guidance, message refinement, and follow-on research priorities.
Bring one live research decision and the evidence already around it.
Start with a real decision: which route to take forward, which message should lead, which concept deserves investment, what the agency should protect, or what needs more evidence before commitment.
Underneath every Unity Arc engagement, the same three layers structure how evidence is read. Three system layers. Multiple decision outputs.
What people say, choose, rate, question, resist, or prioritise — through qualitative or quantitative evidence.
How response forms, strengthens, weakens, or stalls: understanding, credibility, relevance, motivation, fragility.
Which words, claims, and narrative structures carry meaning, confidence, and action — and which weaken under exposure.
The easiest way to assess Unity Arc is to attach it to a primary research moment the team already recognises.
Turn qualitative or quantitative response into clearer decision evidence.
Use existing decks to identify what is already known, where confidence is strong, where evidence is thin, and what needs further support.
Start with one research decision. Use familiar evidence. Compare the added value. Scale only if it earns its place.